Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Celgene Receives European Commission Approvals for Revlimid and Imnovid-Based Triplet Combination Regimens for Multiple Myeloma

Celgene Corporation announced that the European Commission approved two new triplet regimens based on the company’s proprietary IMiD treatments, Revlimid (lenalidomide) and Imnovid (pomalidomide).

Read More »

Nestle makeover advances with $10 billion sale of skin health unit

Nestle entered exclusive talks to sell the company’s skin health business to a consortium led by EQT Partners for 10.2 billion Swiss francs ($10.1 billion), as the food group shifts its portfolio in response to changing consumer demands.

Read More »

Lilly’s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.

Read More »

Novartis data at AAN show Gilenya is only disease-modifying therapy with proven superiority versus glatiramer acetate in RRMS

Novartis announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).

Read More »

AstraZeneca Halts Phase III CLL Trial Early After Primary Endpoints Are Met

AstraZeneca’s Calquence (acalabrutinib) hit the mark in a Phase III trial of previously treated patients with chronic lymphocytic leukemia (CLL).

Read More »

Pfizer gets U.S. approval for $225,000 a year heart drug

The U.S. Food and Drug Administration approved Pfizer Inc.’s oral drug tafamidis to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy.

Read More »

Infuse storytelling with imagination and light up the brain

Our brains are hard-wired to receive information primarily through storytelling. The more imaginative, the better. Imagination is a powerful tool.

Read More »

GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data

In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.

Read More »

AACE Meeting: New Data from Phase 3 OPTIC Study

Horizon Pharma announced that new data from the Phase 3 confirmatory study evaluating teprotumumab for treating active thyroid eye disease were presented as part of a late-breaking oral presentation at the 2019 AACE Scientific and Clinical Congress.

Read More »

Health apps may not disclose sharing your personal information

While nine out of 10 phone apps for depression and smoking cessation assessed in a recent study were found to be sharing user data with third parties, only two out of three disclosed they were doing so.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom